CHAM
TRAW icon

Clear Harbor Asset Management’s Traws Pharma TRAW Stock Holding History

Clear Harbor Asset Management’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-22
Closed -$51K – 282
2018
Q2 		$51K Buy
+22
New +$63.9K 0.01% 249

Other funds holding TRAW

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
TCP
Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Clear Harbor Asset Management's TRAW Position: Q3 2018 in Review

Clear Harbor Asset Management sold out of Traws Pharma (TRAW) in Q3 2018, closing a stake of 22 shares — an estimated $51K sold.

Clear Harbor Asset Management first reported a position in TRAW in Q2 2018 and held it in 1 quarter. The position peaked at $51K in Q2 2018. 13 funds tracked by Wall St. Rank hold TRAW as of Q3 2018.

  • Clear Harbor Asset Management reported no remaining Traws Pharma position as of Q3 2018 after selling out during the quarter.
  • Clear Harbor Asset Management sold 22 Traws Pharma shares in Q3 2018, an estimated $51K.
  • Clear Harbor Asset Management first reported a position in Traws Pharma in Q2 2018 and held it in 1 quarter.
  • Clear Harbor Asset Management's Traws Pharma position peaked at $51K in Q2 2018.
  • 13 funds tracked by Wall St. Rank held Traws Pharma as of Q3 2018.

Based on Clear Harbor Asset Management's 13F filing for Q3 2018, filed 26 Oct 2018.